Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2026 07:00 ET | Source: Herantis Pharma plc

Herantis Pharma releases 2H and FY 2025 report today

Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies...
February 19, 2026 10:35 ET | Source: Herantis Pharma plc

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma...
November 26, 2025 07:00 ET | Source: Herantis Pharma plc

Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096

Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying...